• Laboratory medicine’s expanding role (00:15): Learn how laboratory medicine touches nearly every aspect of healthcare — and why its importance will continue to grow with the integration of AI.
• An inspiring patient story (05:22): Hear how a young patient with a rare disease is able to pursue her passion for dance thanks to advances in laboratory medicine.
• Advances in testing for autoimmune blistering diseases (07:29): Discover how novel diagnostic tests are helping clinicians better tailor treatment for patients with complex skin conditions.

Note: Information in this post was accurate at the time of its posting.

Resources

• Immunodermatology: Unmatched testing expertise
• A family's journey with an ultra-rare disease: Isabel the incredible

• AI systems for healthcare guidance (00:36): Learn how patients and consumers are using AI tools to better understand their health information.
• Diagnostic’s digital innovation journey (07:43): Explore the evolution of digital advances, their impact on care today, and what lies ahead.
• Guidance for selecting new tools (20:51): Gain practical guidance on selecting new digital tools in the laboratory.

Note: Information in this post was accurate at the time of its posting.

Resources

• From Intake to Interpretation: How AI Assists Lab Teams Today
• Making the Promise of AI a Reality in Laboratory Medicine and Pathology

• Public policy insights for 2026 (00:34): Dr. Bill Morice shares insights on reimbursement and AI-related policy developments following an association meeting in Washington, D.C. 
• An unprecedented year for test development (04:45): Discover how Mayo Clinic’s record year for test development delivers value to Mayo Clinic’s patients and Mayo Clinic Laboratories’ clients.
• Novel preeclampsia testing (08:13): Learn how new clinical testing helps physicians improve outcomes for women at risk for preeclampsia and their babies.

Note: Information in this post was accurate at the time of its posting.

Resources

• 4 steps to establishing a new approach to innovation 
• Innovation beyond the bench: Translating science into better diagnostics and outcomes
• Preeclampsia: Empowering confident decision-making through preeclampsia risk assessment
• Assay stratifies pregnant women's preeclampsia risk: Joshua Bornhorst, Ph.D. 
• Preeclampsia sFlt-1/PIGF Ratio, Serum (Mayo ID: PERA)

• Transplant testing innovations (00:57): Discover how advances in clinical diagnostics are improving transplant outcomes at Mayo Clinic. 
• Advances reshaping rheumatoid arthritis diagnostics (06:06): Learn how early-stage research and emerging tools are reshaping care for patients with rheumatoid arthritis. 
• New test for peripheral neuropathy (08:18): A novel test created to support care for patients with a recently identified condition now supporting research to advance care. 

Note: Information in this post was accurate at the time of its posting.

Resources

• Rewriting the future of rheumatoid arthritis: How early detection is transforming prevention
• Cultivating a comprehensive test menu for organ transplant patients
• Screening test for sorbitol dehydrogenase deficiency-related neuropathy (SORD)
• Innovative SORD test provides clarity for two young patients: Justin Fugelsang and Zach Pedowitz

• Protecting Access to Medicare Act (PAMA) delay (01:09): Dr. Morice shares what the latest delay of PAMA means for laboratories.
• FDA guidance on wearables (02:23): Learn about recent FDA guidance that allows more non‑invasive wearables to be classified as wellness devices. 
• Collaboration as a driver of innovation (06:20): Discover why collaboration is critical to advancement in clinical diagnostics.

Note: Information in this post was accurate at the time of its posting.

Resources

• Groundbreaking collaborations
• Mary Jo Williamson offers four steps to maximize collaboration benefits
• Dr. Bill Morice shares how a platform for collaboration transforms diagnostics
• “Answers From the Lab” podcast: “Forging Collaborations That Deliver Better Outcomes”

• PAMA reform update (00:34): Get the latest on PAMA delays and the new Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act.
• Creepy Dreadful Wonderful Parasites (04:24): Go behind the scenes of the 800 parasite cases Dr. Pritt has featured on her long-running blog.
• Logistics at Mayo Clinic Laboratories (08:09): Learn how the team manages and tracks the 40,000 samples that arrive each day.
• Process improvement and resiliency (12:49): Discover how the logistics team continues to innovate and evolve to support clients more efficiently and effectively.

Note: Information in this post was accurate at the time of its posting.

• JP Morgan Healthcare Conference (00:34): Dr. Morice shares his top observations and takeaways after attending this year’s conference. 
• Artificial intelligence (06:02): Anticipated benefits and risks of AI developments predicted in 2026.
• Reimbursement and regulation (13:43): Why reimbursement and regulation continue to be areas of significant interest in clinical diagnostics. 

Note: Information in this post was accurate at the time of its posting.

Resources

• Transforming laboratory medicine through AI: From promise to practice
• "Answers From the Lab" podcast: Breakthroughs and Trends That Defined Lab Medicine in 2025
• "Answers From the Lab" podcast: PAMA Update and Accelerating Research and Development With BioPharma Diagnostics

• Direct-to-consumer testing (00:38): Explore the rise of direct-to-consumer testing and the challenges that accompany it. 
• Evolving expectations for innovation (05:38): Understand why patient and clinician expectations are rising and how that is reshaping diagnostics.
• Safeguarding advances (07:23): Learn the foundational principles that protect quality and safety amid rapid innovation.
• Strategies for accelerating innovation (10:33): Discover practical ways to responsibly deliver novel solutions more quickly.

Note: Information in this post was accurate at the time of its posting.

Resources

• Five ways to move faster without compromising trust in diagnostics
• "Answers From the Lab” podcast: Breakthroughs and Trends That Defined Lab Medicine in 2025
• 360Dx: 2025 highlights and takeaways for the clinical lab industry

• Staying healthy during the holidays (00:18): Discover how to protect yourself and others as a new influenza strain, holiday gatherings, and increased travel raise the risk of spreading viruses. 
• 2025 breakthroughs and trends (04:31): Learn more about the technologies, regulations, and innovation influencing the future of clinical diagnostics. 

Note: Information in this post was accurate at the time of its posting.

Resources

• "Answers From the Lab” podcast: Innovations Set to Shape the Industry in 2025
• Dr. Morice shares trends and predictions for 2025
• Mayo Clinic Minute: How to prepare for the influenza season
• Mayo Clinic Minute: Wash your hands for better health
• Vaccines and viruses: Protecting health across generations

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss Protecting Access to Medicare Act (PAMA) reform and the first reported death from alpha-gal syndrome. Later, Dr. Pritt welcomes Chris Garcia, M.D., Mayo Clinic Laboratories’ chief digital innovation officer and medical director of BioPharma Diagnostics, to explore how biopharma diagnostics advance research and development. 

• PAMA reform update (00:33): Get the latest on where reform to PAMA stands following the federal government’s reopening.
• Alpha-gal syndrome case (03:22): Learn about the first known death from alpha-gal syndrome and diagnostic testing for this tick-bite-triggered red meat allergy.
• Biopharma’s role in research and development (07:52): Discover how biopharma diagnostics fuel innovation and how digital tools are expanding its future impact.  

Note: Information in this post was accurate at the time of its posting.

Resources

• BioPharma Diagnostics: Connecting pharma and biotech
• Tick-borne disease: An expanding geographic threat

• PAMA reform update and new RESULTS Act (00:30): Hear about options under consideration for PAMA reform, including the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act.
• When cerebrospinal fluid (CSF) metagenomics benefit patient care (06:04): Explore how CSF metagenomics work and when it is appropriate to use this advanced diagnostic tool in clinical practice.
• Advancement and innovation in metagenomics (18:15): Discover how recent and upcoming innovation is expanding metagenomic testing capabilities. 

Note: Information in this post was accurate at the time of its posting.

Resources

• Answers From the Lab podcast: Developments for LDT Regulation and Laboratory Reimbursement: Bill Morice, M.D., Ph.D.
• Metagenomics: Identifying elusive pathogenic microorganisms

• Testing for viruses appearing closer to home (00:45): Gain insights on using available testing to manage measles and detect chikungunya, which was recently transmitted in the U.S. for the first time in years. 
• Collaborating for more coordinated care and innovation (06:04): Explore how strategic partnerships in diagnostics foster innovation and enable a more integrated approach to clinical decision-making.
• Building successful collaborations (12:16): Discover practical insights into establishing and maintaining collaborations that deliver meaningful value to all involved. 

Note: Information in this post was accurate at the time of its posting.

Resources

• Answers From the Lab Podcast: How the Evolving Role of Diagnostics and Platforms Impact Healthcare: Bill Morice, M.D., Ph.D. 
• Dr. Bill Morice shares how a platform for collaboration transforms diagnostics
• Mary Jo Williamson offers four steps to maximize collaboration benefits

• New podcast format launch (00:25): Drs. Morice and Pritt introduce the exciting new format for “Answers From the Lab,” including the addition of in-depth expert segments.   
• Drug-resistant infections (02:05): Discover how clinical diagnostics play a critical role in combating the growing threat of antibiotic resistance. 
• Diagnostics’ role in advancing precision medicine (13:28): Learn how diagnostics, specifically drug monitoring, are advancing personalized therapies and contributing to better outcomes. 

Note: Information in this post was accurate at the time of its posting.

Resources 

• Therapeutics testing: A clear path to accurate answers 
• Therapeutics testing at Mayo Clinic Laboratories 
• WHO warns of widespread resistance to common antibiotics worldwide 
• Tests for infectious disease detection and identification 

 
Connect with Us 

• Is there a question or topic you’d like us to explore in a future episode? Email us at mayocliniclabs@mayo.edu. 
• Learn more about our hosts and guests and connect with them on social media.  
  • Bobbi Pritt, M.D.  Bio  |  LinkedIn 
  • Bill Morice, M.D., Ph.D. Bio  |  LinkedIn 
  • Paul Jannetto, Ph.D. Bio  |  LinkedIn

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, discuss recent regulatory and policy developments. Together, they explore:

• FDA rescinds rule on LDTs (00:48): The FDA has officially withdrawn its rule that would allow oversight of laboratory-developed tests (LDTs) as medical devices. The conversation explores what this decision means and what might come next for LDT regulation.
• PAMA reform update and new RESULTS Act (05:13): The newly introduced Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act aims to address reimbursement for laboratory tests.
• Getting engaged (12:37): Why it is important to understand new regulatory policies and help others understand their implications for the industry.

Resources

• Find past “Answers From the Lab” podcasts on LDTs and PAMA

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and Elitza Theel, Ph.D., director of the Infectious Diseases Serology Laboratory at Mayo Clinic, discuss the latest developments in self-collection testing for women’s health and beyond. Together, they explore:

• New podcast format launching (00:01): Dr. Pritt previews exciting changes coming to “Answers From the Lab.” 
• Emerging self-collection tests (01:21): Explore the growing range of self-collection tests now available for use in both clinical settings and at home.
• Validation of self-collection tests (03:19): Learn how laboratorians validated recent self- and home-collection tests to ensure quality and accuracy. 
• Benefits for patients and public health (06:56): Understand the benefits self-collection tests offer to patients and how the tests impact public health.
• Limitations and implementation considerations (08:23): Review key factors to consider when incorporating self-collection testing into clinical care.
• Future innovation (11:34): Insights into where self-collection testing may evolve in the years ahead.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, discuss troublesome organisms making headlines. Together, they explore:

• Vibrio vulnificus (01:09): How people get this “flesh-eating” bacteria, how it affects patients, and a recent case that brought it into the spotlight.
• Staying safe (03:44): Discover when to seek medical attention and how knowledge can protect you as Vibrio vulnificus bacterium becomes more prevalent. 
• New World screwworm (06:50): How this parasitic infection damages human tissue, how it was previously eradicated, and why it's making the news again. 
• ABCs of protection (12:16): A simple reminder to avoid exposure, use bug spray, and wear protective clothing to shield against hazardous organisms.
• Laboratory as first line of defense (13:34): Laboratorians have a critical role in identification and monitoring broader trends when these types of cases arise. 

Resources

• A-Zs for prevention and exposure risks

(00:32)
Would each of you share a little bit about yourselves and your background?

(01:42)

Could you provide us with an overview of the whole exome reflexing panel?

(02:53)
 Is this different from our whole exome sequencing panel and our whole exome reanalysis panel?

(04:00)
 Tell us more about who benefits from this test.

(06:17)
 What is the clinical utility of this testing?

(08:07)

Would you help providers understand how to go about ordering?

(11:23)

Could you tell us more about the types of variants identified by this test?

(13:39)

Based on those performance characteristics, how does our test match up to other exome tests available in the market?

(14:30)

Are there any other unique features you would like to highlight?

(15:57)

What is the turnaround time for the reflex panel?

(16:14)

Can the results from the WESPR test be reanalyzed in the future as new genetic knowledge emerges?

(16:56)

How are variants reported, especially variants of uncertain significance? And does the report include recommendations?

(19:31)

Would you summarize the benefits of the WESPR at Mayo Clinic Laboratories?

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and Matthew Binnicker, Ph.D., a microbiologist and virologist and chief scientific officer of Mayo Clinic Laboratories, discuss recent developments in viral infections. Together, they explore:

• Shope papilloma virus in rabbits (01:05): Unusual growths raise concern, though the virus poses minimal risk to humans and has actually benefitted research for other papilloma viruses. 
• Chikungunya virus (07:07): What it is, how it spreads, who is at risk, and best practices for testing. 
• Back-to-school viral trends (12:19): Common viruses that circulate during the school season, tips for keeping kids safe, and guidance for physicians on when to test. 
• The laboratorian’s role (18:27): How laboratory professionals contribute to managing viral infections within hospital systems and the broader community.

Resources

• Forbes article: Is the ‘zombie rabbits’ virus a threat to humans?
• Mosquito-borne disease testing overview
• Mosquito-borne testing algorithms and interpretations
• Search our test catalog for more on testing for viral infections

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, discuss recent news about the use of artificial intelligence (AI) tools in healthcare. Together, they explore:

• Applications of AI tools in clinical diagnostics to identify dementia, cardiovascular conditions, and parasites.
• Ethical considerations, including global disparities in access to AI tools and environmental impacts.

Resources

• Use of artificial intelligence and digital slide scanning for detection of intestinal protozoa in trichrome-stained stool specimens
• Mayo Clinic's AI tool identifies 9 dementia types, including Alzheimer's, with one scan
• AI computing power is splitting the world into haves and have-nots - The New York Times

• Observations from this year’s tick season as we approach the end of July — a peak month for tick-borne disease transmission — along with trends in reported tick-borne pathogens over the past two decades.
• Algorithms developed by Mayo Clinic to guide clinicians in selecting the right tests for tick-borne and mosquito-borne diseases. 
• The emergence of rare and esoteric infections and the challenges posed by vectors that carry and transmit multiple pathogens in a single bite.
• Shotgun metagenomics’ growing role in the diagnosis of vector-borne infections.

More resources
Read "Update on North American tick-borne diseases and how to diagnose them" in the Journal of Clinical Microbiology for more insights from Drs. Pritt and Theel. You can also explore tools and information from Mayo Clinic Laboratories, including region-specific details, algorithms, prevention tools, and more. 

Common summertime illnesses, along with tips for prevention. 

• How investment in diagnostic tools influences innovation in the laboratory.
• The potential impact of growing interest in AI investments. 
• The investment interest in liquid biopsy and its potential implications for clinical decision-making.
• How AI development may accelerate adoption of mass spectrometry, proteomics, and similar advancements in clinical laboratories. 

(00:32)
 Could you both please tell us a little bit about yourself and your background?

(02:23)
 Could you please give the audience a brief overview of this assay? 

(03:53)
 Which patients should have this test, and when should it be performed?

(04:49)
 What alternative testing options are available, and how do these compare to the new, expanded panel that we're going to be offering?

(08:20)

How are the results used in patient care?

• The significant interest in diagnostics for the advancement of cancer care.
• The Joint Commission’s collaboration with the Coalition for Health AI to establish guidelines for the responsible use of artificial intelligence. 
• The growing understanding that platforms offer an opportunity to expand access and make knowledge more accessible as platform-driven solutions become a reality.
• The role of laboratorians in guiding the ethical and effective use of data and emerging technologies — and what this means for educating future healthcare professionals.
• The critical importance of values and ethics in deploying new tools.

(00:32)
Can you tell us a little bit about yourself and your background?

(01:33)
 Could you give us a brief overview of this assay?

(02:47)
 Which patients should have this testing, and when should it be performed?

(03:48)
 How would the results be used in patient care?

Speaker 3: (00:33)
 Could you tell us a little about yourselves and your backgrounds?

Speaker 3: (01:41)
 Dr. Taler, could you provide us with a brief background on resistant hypertension?

Speaker 3: (03:43)
 Can you provide a little bit more background on patients who aren't taking their medications?

Speaker 3: (05:11)
 How do physicians currently assess whether patients are taking their medications?

Speaker 3: (07:03)
 Dr. Lieske, could you tell us how this new assay can be used to help physicians manage their patients with hypertension?

Speaker 3: (09:43)
 Dr. Taler, can you tell us how doctors can use this new testing to manage their patients?

• The high prevalence of peripheral neuropathy and why early diagnosis is important. 
• The complexities involved in diagnosing the condition.
• Symptoms that should prompt clinicians to order advanced testing early in the diagnostic process.
• How algorithms are enhancing the use of testing to complement other diagnostic tools.
• Ongoing discovery related to specific antibodies associated with neuropathies.

Learn more in our e-book, "Peripheral neuropathy: Cutting through diagnostic dissonance with an algorithmic approach."

(01:14)
Could you give us a brief overview of this assay?

(02:06)
Can you explain the differences of the qualitative and quantitative methods and why we made the change to a quantitative adenovirus method?

(04:00)
When is this test typically ordered for transplant patients? Is it used throughout their treatment?

(06:56)

Could an immunocompromised person be unknowingly infected?

(07:31)

Is our quantitative method approved for pediatric patients?

(08:00)

How are the test results used to treat patients?

(10:36)

What other infections might providers consider alongside adeovirus?

• Emerging innovations in mass spectrometry, next-generation sequencing, automation, and artificial intelligence. 
• Fierce competition in the global manufacturing landscape as new companies enter the market. 
• Geopolitical dynamics influencing where innovations are deployed. 
• Why laboratory professionals need to drive innovation implementation to maximize benefits for clinicians and their patients.

• Growth in revenue
• Growth in lab charges
• Growth in ancillary services
• Hospital length of stay
• Control over expenses

You can also find more in-depth information on this topic in “Maximizing your health system’s financial performance,” a white paper with data-driven ways laboratories support their organizations. 

• Different diseases patients can get from ticks. 
• Disease prevention, including Dr. Pritt’s A through Z flash cards with tips for people to protect themselves from infectious insects.
• Laboratory medicine’s valuable role in testing and educating providers to diagnose patients quickly and accurately.
• Clinical areas most likely to encounter patients with tick-borne diseases.
• Reliable sources for details about the prevalence of different diseases around the country (e.g., U.S. Centers for Disease Control and Prevention (CDC) and Mayo Clinic Laboratories).

• Details about how the cerebrospinal fluid biomarker test (Mayo ID: ASYNC) benefits patients exhibiting signs and symptoms of clinically uncertain cognitive decline or clinically uncertain Parkinsonian syndromes.
• Groundbreaking science on proteins that Amprion leveraged to create a solution that meaningfully impacts patient care and provides value to clinicians.
• Information physicians receive from the test, and when they should consider ordering it for their patients. 
• Opportunities to change diagnostic journeys by providing accurate, early diagnosis with SAAmplify–αSYN. 

(00:33)
Do you mind telling us a little bit about yourself and your background?

(01:45)
Could you please provide us with an overview of arsenic, how people get exposed, and the laboratory testing for arsenic and arsenic speciation?

(05:25)
Which patients should have this testing, and when should it be performed?

(06:57)
What alternative test options are available, and how does testing at Mayo Clinic compare?

(08:37)

How are the results used in patient care?

• Details about the ruling to vacate the FDA’s rule on LDT oversight. 
• What LDT oversight might look like in the future. 
• How the laboratory medicine industry can help create an oversight approach that is positive for both patients and innovation. 

(00:32)
Could you provide us a with little bit about your background and yourself?

(03:45)
Will you please provide a brief overview of Mayo test 3A5Q?

(06:56)
Which patients should have this testing, and when should it be performed?

(08:15)
 What alternative or complementary tests should be considered?

(09:25)

How are the results used in patient care?

(10:38)

Will you help the audience understand the significance of monitoring tacrolimus levels for transplant rejection?

(12:53)

What alleles are included in this test?

During their conversation, Dr. Morice and Dr. Tan explore:

• Inspiration for developing the liquid biopsy.
• Features that differentiate LiquidHALLMARK® from existing cancer tests.
• Patients who will benefit from the test and how an oncologist might use the results.
• The future potential of liquid biopsy advancements.

• The emergence of retail health locations.
• Three types of care that are well-suited for a retail approach to healthcare.
• The importance of incorporating diagnostics when designing retail health.

Keep up with the latest diagnostic news and Dr. Morice's insights on LinkedIn and X. 

•  The high prevalence of influenza A, avian influenza, measles, and COVID-19. 
• Reliable resources for information on the spread of infectious diseases. 
• Prevention measures and their impact on the spread of infectious diseases. 
• The risks associated with multiple infectious diseases circulating simultaneously at high rates. 

• The advantages and challenges of new types of specimen collection and testing methods, including over-the-counter, at-home, and point-of-care options. 
• Implications home testing has for clinicians and public health. 
• Barriers to making more at-home collection and over-the-counter testing products for STI testing.
• The growing need for tests to detect resistance markers as antimicrobial resistance increases. 

• The benefit of investing in quality management for patients, staff, and the organization.
• How Mayo Clinic’s Department of Laboratory Medicine and Pathology in Rochester evolved and grew its quality management program.
• The advantage of holding 5–10-minute huddles each day.
• How the lab leverages education on quality tools and Gemba Walks to empower all staff to invest in quality management.

They discuss recent business trends in diagnostics and why it is important for pathologists to stay informed about these trends. Their conversation covers: 

• What’s driving a renewed interest in investing in diagnostics.
• Why the knowledge pathologists have is so valuable in the current landscape.
• How the evolving expectations of laboratory professionals will make it important to stay informed about business trends.

(00:32)
Would you mind telling us a little bit about yourself and your background?

(01:58)
Would you give us an overview of membranous nephropathy? 

(07:14)
Could you tell us a little bit about this new assay?

(14:29)
Could you give a little example of how a clinician might use this information to treat their patients differently than how they would've in the past? 
 
 

They discuss Dr. Morice’s recent article in Becker’s Hospital Review, “Nine Developments Predicted to Shape Laboratory Medicine and Diagnostics in 2025,” and go deeper into conversation about: 

• The rapid evolution of artificial intelligence and large language models.
• Digital pathology.
• Proteomics, metabolomics, and mass spectrometry.

Topics of discussion include:

• Specific examples of how they are using automation in the laboratory. 
• Strategies for ensuring a smooth implementation and a positive experience for staff. 
• The potential of automation to support staff and continued patient care excellence amid projected labor shortages in the future. 

Specific topics of discussion include:

• Patterns of transmission and what they indicate about the potential of person-to-person transmission. 
• Tools, tests, and processes that emerged in recent years that are making it easier to understand and track this virus. 
• Remaining unknowns about the virus and how it could evolve. 

Specific topics of discussion include:

• What’s driving the rapid acceleration of AI advancements.
• Ethical concerns and opportunities.
• How expenses, payment models, and culture influence AI advancements.
• The need to rethink training and education amid the rise of AI solutions.

Specific topics of discussion include:

• Recent trends in the spread of H5 bird flu and dengue fever. 
• Why it’s important to think globally when monitoring infectious diseases.
• Extra precautions to take during the holiday travel season to keep you and those around you healthy.

Specific topics of discussion include:

• Innovations creating new possibilities, such as mobile clinics, at-home tests, and artificial intelligence.
• The responsibility of laboratory professionals to help guide the use of these new tools and the importance of collaboration between health systems.
• What’s needed to make solutions scalable and sustainable.

Learn more in Dr. Morice’s “Lab Manager” article. 

Specific topics of discussion include:

• The seven main types of genetic testing, and how clinicians know when and what genetic testing to order.
• Key family history details to collect to inform decisions about genetic testing. 
• How genetic counselors collaborate with physicians and laboratorians to make testing decisions. 
• Recent genetic testing advancements that are improving diagnostics. 

(00:32)
Could you give us a brief overview about your background and yourself?

(02:16)
Could you explain the role of the UGT1A1 gene and its significance in the pharmacogenomics of irinotecan? 

(05:34)
What specific tests do we offer for UGT1A1 at Mayo Clinic Laboratories?

(08:01)
Can you clarify the difference between targeted genotyping and full gene sequencing, and when each method is most appropriate?

(10:36)
Could you elaborate on the specific clinical indications for testing in relation to irinotecan?

(13:27)
How do UGT1A1 test results impact the dosing of irinotecan? What should clinicians consider when using those results? 

(14:02)
Are there any other factors or related genes that should be considered alongside UGT1A1, particularly for cancer therapy?

Specific topics of discussion include:

• Recent increases in outbreaks of infectious diseases, such as pertussis, measles, and polio. 
• The serious side effects of the diseases. 
• What’s fueling the resurgence of these diseases.
• Testing options for infectious diseases and resources for physicians.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss practical steps for protecting yourself and innovations that are making testing and vaccination easier. 

Specific topics of discussion include:

• The importance of vaccinations and preventive measures to keep you healthy. 
• Innovations that are making it possible to provide more at-home options for vaccination and testing and when these options will be most beneficial. 
• The latest status on avian influenza.

Speaker 3: (00:32)
Could you provide our listeners with a little bit about yourself and your background?

Speaker 3: (01:27)
 Could you give an overview of our MLH1 hypermethylation, also referred to as MLHPB in our test catalog? 

Speaker 3: (02:48)
 Can you talk about why your team thought it was really important to develop this test?

Speaker 3: (04:03)
 What patients would this testing really benefit?

Speaker 3: (06:10)

How are the results used in patient care?

Speaker 3: (07:56)
 Anything else you would like our listeners to hear about MLHPB?

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by John Osborn, operations administrator in the Department of Laboratory Medicine and Pathology at Mayo Clinic, who helps lead efforts to prepare for technology disruptions in the laboratory. 

Specific topics of discussion include:

• Immediate considerations when a technology disruption occurs and prioritizing the restoration of systems and processes. 
• How to create strategies and tools to guide decision-making and operations amid multiple outage scenarios. 
• Lessons learned from real life examples, including the importance of clear communication, empowering lab directors to make decisions, and pre-planning for recovery. 
• Preventive measures and risk mitigation strategies you can take today to make it easier to respond during a future incident.

Specific topics of discussion include:

• The phospho-Tau 217 plasma test (Mayo ID: PT217) used to evaluate individuals aged 50 years and older with symptoms of cognitive impairment who are being assessed for Alzheimer’s disease and other causes of cognitive decline.
• The benefits of a blood test versus the other diagnostic methods for Alzheimer’s disease.
• Why early diagnosis is so important for quality of life and treatment planning.
• How tests like Mayo Clinic Laboratories’ PT217 may change the landscape of Alzheimer's research and treatment.

Specific topics of discussion include:

• How these rare disorders are diagnosed through laboratory tests.
• Why platelet transmission electron microscopy is considered the gold standard for diagnosing disorders like Hermansky Pudlak syndrome, Wiskott-Aldrich syndrome, Chediak Higashi syndrome, and Jacobson/Paris-Trousseau syndrome.
• The process involved with developing and validating the PTEM test (Mayo ID: PTEM) at Mayo Clinic.
• The importance of ongoing research and advocacy to enhance care for patients with rare platelet disorders.

Their discussion includes:

• How the United States addresses emerging pathogens and the importance of a partnership between public health laboratories and private or clinical laboratories.
• Why access to testing is vital to prevent pathogen outbreaks and pandemics.
• The need for an effective legal framework around pandemic and hazard preparedness.
• Current diagnostic efforts around mpox, bird flu, and COVID-19, and opportunities to expand at-home testing.

(00:31)
Would you share a little bit about yourself and your background?

(01:11)
 Could you provide us with an overview of this particular peripheral neuropathy? 

(03:09)
 Can you share the background as to how your team learned about this condition and how you considered testing for it?

(04:42)

Would you explain what you saw when you performed the urine test on the first patient?

(05:26)
 Were you able to test additional patients with this condition?

(06:09)

Could you expand on why this urine test is important?

(07:20)
 How does a health care provider order urine testing for SORD deficiency?

(07:59)
 How does this new SORD urine test complement the existing Mayo Clinic Laboratories test menu?

(08:55)

Could you summarize the benefits of ordering this SORD urine test at Mayo?

Their discussion includes:

• Symptoms of lupus and characteristics of the complex disease process.
• The role of laboratory testing in diagnosing and managing long-term treatment for patients with lupus.
• Dr. Thomas’ clinical experience using the Progentec aiSLE® DX Lupus Flare Risk Index and Lupus Disease Activity Index for his patients, and how these tests have enhanced collaborative treatment planning.
• Why these novel tests are a major step forward in expanding diagnostic tools and improving care for patients living with SLE.

Show notes

Speaker 3: (00:32)
 Would you provide a little background on yourself, Dr. Mills?

Speaker 3: (01:19)
 Dr. Dubey?

Speaker 3: (02:07)
 Can you give a brief overview of our demyelinating test and recommended use?

Speaker 3: (03:52)
 Can you discuss how this new test will assist in a patient's journey?

Speaker 3: (05:46)
 Can you tell us some of the unique features of this test?

Speaker 3: (08:09)
 Dr. Dubey, as a neurologist, how does this test set us apart in the market?

Speaker 3: (11:05)
 Could you summarize the benefits of having both a demyelinating panel and an axonal panel?

Speaker 3: (11:40)
 Why should a patient have an axonal or demyelinating test versus a sensory and motor test for peripheral neuropathy?

Their discussion includes:

• The Progentec aiSLE® DX Lupus Flare Risk Index that uses an algorithm to calculate a flare risk index, which assigns a score based on a patient's risk of a forthcoming lupus flare.
• The Progentec aiSLE® DX Lupus Disease Activity Index that characterizes a patient’s current disease activity into low, moderate, or active states.
• How these two tests were developed and for whom they are recommended.
• Why these tests are a significant development and how they enhance the quality of life for patients living with SLE.

Speaker 3: (00:32)
 Would you tell us a little bit about yourself and your history with this testing?

Speaker 3: (01:25)
 Would you tell us a little more about this assay?

Speaker 3: (04:57)
 Which patients should have this testing and when should it be performed? 

Speaker 3: (05:30)
 What alternative tests exist and how do they compare?

Speaker 3: (06:28)
 How are the results used in patient care?

Their discussion includes:

• Why there is an increased focus on Alzheimer’s disease in the diagnostics industry.
• The development of groundbreaking blood tests that can detect Alzheimer’s-related biomarkers.
• The importance of accurate testing to avoid false positives.
• The role of laboratory scientists in guiding appropriate test usage.
• The promising new treatment options and the need for informed decision-making in a patient’s healthcare journey.

Their discussion includes:

• Insights from Dr. Morice’s participation in an Advisory Board webinar about 2024 lab market trends.
• Why there is an increased demand for laboratory testing.
• The opportunities that come with digital pathology, at-home testing, and remote diagnostics.

Specific topics of discussion include:

• Background information on the monkeypox virus, and the current outbreak situation.
• What is contributing to the rapid spread of mpox in the Democratic Republic of the Congo and neighboring countries.
• How the current mpox outbreak compares to the global outbreak in 2022, and lessons learned that could be applied today.
• Testing options for diagnosing mpox.
• What can be done to control the spread of mpox and prevent future outbreaks. 

Their discussion includes:

• Summer cases of COVID-19.
• H5N1 (avian influenza) activity and testing options.
• Increasing dengue fever infections.
• Outbreaks of listeria and cyclospora.
• The importance of public-private partnerships in preventing disease outbreaks and increasing access to testing.

Speaker 4: (00:32)
 Please give the audience a little information about yourself and your background.

Speaker 4: (02:12)
 Please give the audience a brief overview of this assay.

Speaker 4: (04:34)
 Which patients should have this testing and when should it be performed? 

Speaker 4: (05:50)
 What alternative testing options are available and how do these compare?

Speaker 4: (06:47)
 How are the results used in patient care?

Their discussion includes:

• What’s happening in the global diagnostics industry and takeaways from visiting Saudi Arabia and Italy.
• Why countries are looking toward building their own biomanufacturing and diagnostic resources, and the impacts of a global supply chain.
• The evolution of digitalization and cybersecurity.

Specific topics of discussion include:

• The characteristics and symptoms of dengue virus.
• Current dengue activity in the United States, why cases are increasing, and how it may impact public health.
• Whether an individual infected with dengue has future immunity against the virus.
• Laboratory tests used to detect and diagnose dengue.
• How to protect against dengue and other vector-borne diseases.

Their discussion includes:

• The benefits and pitfalls of using AI in clinical settings.
• Important factors to consider before implementing AI tools in the laboratory.
• A successful AI use case from the Parasitology Lab at Mayo Clinic, and how it enhanced turnaround times and staff satisfaction.

Their discussion includes:

• A summary of the Supreme Court ruling on June 28 to overturn the 1984 Chevron v. Natural Resources Defense Council decision, and how that impacts the power of federal agencies and the interpretations of the laws they administer.  
• How this decision may impact current healthcare issues like reimbursement and the U.S. Food and Drug Administration’s (FDA) final rule on regulating laboratory-developed tests as medical devices.
• The ambiguity of what comes next, and the importance of engaging members of Congress on these important decisions.

Specific topics of discussion include:

• How Mayo Clinic came to be involved in the project, and what historians were hoping to learn from the test results.
• The technical process of preparing, handling, and testing Beethoven’s hair.
• What the test results revealed about Beethoven’s health.
• An overview of Mayo Clinic’s Metals Laboratory and the specialized testing that occurs in the lab.

Their discussion includes:

• The recent rise in COVID cases and how the new FLiRT variants of the virus are affecting the immune system.
• Updates on avian influenza activity and the risk for more mutations and human infections.
• How the U.S. Centers for Disease Control and Prevention (CDC) is responding to the avian flu outbreaks and how laboratories are preparing to support testing needs.
• Reminders of how to best protect yourself and your loved ones from infectious diseases this summer.

Their discussion includes:

• Key takeaways from the recent conference hosted by Mayo Clinic Platform.
• What constitutes a platform and how the model is being implemented in the healthcare industry.
• How the platform model can transform the way healthcare is delivered, and the implications this transformation has on laboratory medicine and pathology.

(00:32)
 Could you please give our listeners an overview of your role at Mayo Clinic?

(01:22)
 What updates are happening in our laboratory to increase specificity when we receive a patient's serum and CSF for most of the CNS evaluations?

(03:48)
 Why are these updates and additions important in the larger disease state?

(06:16)
 Could you expound upon the relationship between the clinical practice and the lab?

(08:32)
 What do these changes mean for patient care?

(10:27)
 What about the inclusion of AMPA in the pediatric evaluation, and the inclusion of IgLON5 with autoimmune axonal?

(12:58)
 How does your lab discern when it's time to add a biomarker?

(15:44)
 What are you most excited about?

Their discussion includes:

• How a person infected with measles recently traveled through a U.S. airport, and the severity of the measles virus.
• The continued deadly spread of avian flu among wild birds, domestic poultry, and cattle, and the infection of a third human.
• Avian flu vaccine development and the importance of emergency preparedness.
• The American Clinical Laboratory Association’s (ACLA) lawsuit against the U.S. Food and Drug Administration (FDA) regarding the agency’s final rule to treat laboratory-developed tests as medical devices.

(00:32)
 Could you tell us a bit about your background and your role at Mayo Clinic?

(01:26)
 How do the tests that are coming live relate to the larger disease state of neurological disorders?

(02:44)
 Can you share a little bit about the methodology we're using for these particular biomarkers? 

(05:15)
 How was PDE10A discovered?

(06:48)
 Anything you would add?

(07:50)
 Remind us which phenotype-specific assays these biomarkers are being added to, and how physicians should determine whether this testing is appropriate?

(09:55)
 What does early detection of these biomarkers mean for the patient's prognosis, diagnosis, treatment, etc.?

(12:33)
 What are you most excited about with the launch of these tests?

Their discussion includes:

•  Dr. Lucas’ extensive pathology and research background and his journey to Mayo Clinic. 
• His goals for expanding DLMP’s research activities and advancing innovation in diagnostics.
• How laboratory research has evolved over his career and how researchers can continue to make progress despite obstacles.
• The importance of having good mentors, collaborating with others, staying curious, and remaining persistent to achieve goals.

Specific topics of discussion include:

• The current situation of avian flu activity across the world and throughout the United States, including outbreaks in poultry, U.S. dairy cows, and one recent human case.
• How this outbreak is different than previous ones, and the current public health risk.
• Resources for testing humans for avian flu.
• What we know about the new “FLiRT” variants of COVID-19 and how they might impact public health in the months ahead.

(00:31)
 Can you tell us a little about yourself and your background — Beth?

(01:24)
 Stephanie, what about you?

(01:42)
 Dr. Jenkins, a little bit about yourself and your background, please?

(02:25)
 Could you provide a brief overview of the new MayoComplete Solid Tumor assay and the enhancements we've provided?

(04:02)
 What changes did you incorporate into the test?

(04:57)
 Why are copy number variants and loss of heterozygosity important, and how are they used in patient care?

(07:12)
 Does including these genes guide patient care in a more valuable way?

(07:51)
 What alternative test options are available and how do they compare to the MayoComplete Solid Tumor Panel?

(10:27)
 Is having many options available in a one-stop shop important to help guide patient management?

(11:57)
 Do you have anything else you'd like to add about the MCSTP enhancements and what the new test assay will deliver in terms of clinical utility or patient care?

Show notes

Speaker 3: (00:32)
Can you provide a little background about your role here at Mayo Clinic and experience with this disease state?

Speaker 3: (01:21)
 Can you give us an understanding of rapidly progressive dementia? How is it different and what should physicians be looking for?

Speaker 3: (03:13)
 You mentioned "syndromic" and that there are several diseases underneath that, one of them being Creutzfeldt-Jacob. Can you explain the others in a bit more detail? What makes them each unique under the heading of rapidly progressive dementias?

Speaker 3: (05:29)
 Does that encompass it: prion diseases, then the neurodegenerative bucket, then autoimmune?

Speaker 3: (06:03)
 Can you speak to the components of the new Creutzfeldt-Jacob disease-specific evaluation and the rapidly progressive dementia evaluation, and the assays that they're performed on?

Speaker 3: (09:30)
 Anything you want to add to that summary of the assays' components?

Speaker 3: (11:09)
 Can you explain the role — or lack thereof — of the 14-3-3 protein biomarker, according to our research?

Speaker 3: (13:44)
 Which patients should get this testing, and who should not?

Speaker 3: (17:22)
 What does it mean if the results come back positive and if the results come back negative?

Speaker 3: (21:57)
 What are you most excited about with these tests?

Their discussion includes:

• Dr. Hsi’s experience in the field of pathology and what he is looking forward to working on as the new chair of the Department of Laboratory Medicine and Pathology (DLMP) at Mayo Clinic.
• Some common challenges facing laboratory professionals today and ways to overcome them.
• Advancements and trends in pathology and staying current with new developments.
• Words of advice for pathologists who are beginning their careers.

(00:32)
 Can you tell us a little bit about yourself and your background?

(01:46)
 Can you please provide an overview of laboratory testing for substance use disorders and specifically Mayo Clinic's new oral fluid controlled substance monitoring option?

(03:47)
 Which patients should have this testing and when should it be performed?

(05:16)
 What alternative test options are available and how do these compare?

(06:31)
 How are the results used in patient care?

Their discussion includes:

• Highlighting key points, exceptions, and the phased implementation plan of the final rule.
• How the FDA’s final rule compares to its proposed rule from last year.
• How the news may impact laboratories, health systems, health agencies, and manufacturers.
• Uncertainties that still remain regarding the future of laboratory-developed tests.

Specific topics of discussion include:

• Background information on antimicrobial resistance and why it is a growing threat to global health.
• What is being done to address the problem, and Dr. Patel’s work as a member of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria.
• How laboratorians and pathologists can advocate for continued action on antimicrobial resistance.

(00:31)
 Could you please provide a little bit about yourself and your background?

(01:30)
 Would you please share a brief overview of the UBA1Q assay?

(02:13)
 Would you provide an overview of VEXAS syndrome?

(05:30)
 When is this testing recommended during care for patients who have a suspected inflammatory condition or VEXAS syndrome?

(06:38)
 What advantage does this assay provide over other methodologies?

(10:13)
 Could you share further why diagnosis is so important for these patients?

(12:40)
 Is there anything else you'd like to comment about the assay?

Their discussion includes:

• The latest news about the U.S. Food and Drug Administration’s (FDA) proposed rule around regulating lab-developed tests.
• New testing innovations for Alzheimer’s disease and cognitive impairments, including Mayo Clinic Laboratories’ plasma biomarker testing for Alzheimer’s disease. 
• The importance of being responsible lab stewards and working closely with clinicians to understand how different testing approaches drive decision-making in healthcare settings.

(00:32)
 Could you provide us with a little bit of information about yourself and your background?

(01:18)
 Can you start with a brief overview of the assay?

(02:13)
 Which patients should have this testing and when should it be performed?

(03:21)
 Are there alternative test options available and how do those compare with the folate receptor alpha assay?

(03:57)
 How are the results used in patient care?

Their discussion includes:

• Key takeaways from the Becker’s Healthcare Annual Meeting and the College of American Pathologists’ (CAP) Pathologists Leadership Summit.
• The resurgence of measles cases and recent activity of bird flu (H5N1).
• Tips for staying engaged and being the voice for patients.

(00:32)
 Do you mind giving the audience more information about yourself and your background?

(01:53)
 Could you please give a brief overview of this assay?

(03:35)
 Which patients should have this testing and when should it be performed?

(04:57)
 How are the results used in patient care?

(06:59)
 Other monoclonal antibody therapies are usually monitored by a combination of drug quantification and analysis of antidrug antibodies. How is this test being offered?

Specific topics of discussion include:

• The types of tick-borne diseases found throughout the United States.
•  Algorithmic approaches and testing methods used to diagnose tick-borne diseases.
• Helpful resources for clinicians, including Mayo Clinic Laboratories’ Acute Tickborne Disease Testing Algorithm and Lyme Neuroborreliosis Diagnostic Algorithm.
• New tests recently developed by Mayo Clinic Laboratories to aid in the diagnosis of tick-borne disease, including:
  • A broad range bacterial PCR and sequencing test for tick-borne bacteria and some zoonotic bacterial pathogens that may have a similar presentation (Mayo ID: BRBST).
  • Molecular PCR testing to detect the viral RNA of Heartland virus in spinal fluid (Mayo ID: HRTVC) and serum (Mayo ID: HRTVS).
• Preventing tick bites.

(00:32):

Dr. Algeciras, could you just provide a little bit of background on your role at Mayo Clinic?

(01:45):

So before we get into the test itself, can you just explain a little bit about the disease state and especially some of the recent changes?

(07:39)
 So can you explain a little bit more about what the results that our clients will receive look like?

(10:30)
 Can you just give a quick overview of how our test is unique compared to those on the market?

(12:24)
 What patients should have this testing performed, Dr. Algeciras and if you have any tips on which patients should not, please include that as well?

(14:42)
 Let's talk now about how those results are used in patient care.

(16:31)
 One more question, just summarize for our listeners what you're most excited about with this new test.

Their discussion includes:

• The surge of dengue cases in Latin America, and best practices for tick and mosquito bite prevention.
• Advancements in laboratory tests and technology used for colon cancer screening.
• Issues with insurers paying for new screening technology versus routine screening methods.
• How laboratorians can help educate physicians and policymakers on how innovative laboratory tests create value for patients and the entire healthcare system.

(00:33)
 Do you mind giving us a brief introduction of yourself and what you do at Mayo?

(01:45)
 Can you tell us a little about the test and how it came to be?

(03:00)
 Could you explain the types of patients this test would be best suited for and how a provider might determine if their patient would benefit from this?

(03:32)
 Would you please explain why the algorithm is recommended and where in the algorithm this test fits?

(04:36)
 What makes this test different from what's currently available to providers?

(05:38)
 How can the information be used in patient care? And can you talk a little bit about how the diagnosis can be clarified by using this assay, why it's important, and how the results would impact a patient's care and treatment plan?

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Matthew Binnicker, Ph.D., professor of laboratory medicine and pathology and clinical virologist at Mayo Clinic, to discuss why measles is in the news again and how we can prevent measles outbreaks.

Specific topics of discussion include:

• The symptoms, characteristics, and complications of the measles virus.
• The recent rise in measles cases and outbreaks being reported across the United States.
• The importance of vaccination in preventing the spread of the highly contagious virus.
• Why the measles laboratory test was eventually developed, and testing options available through Mayo Clinic Laboratories.

(00:33)
 Dr. Hasadsri, can you tell the audience a little bit about yourself and your background?

(01:32)
 And Ms. Cabral?

(02:03)
 Can you please give the audience a brief overview of this assay?

(03:33)
 Which patients should have this testing and when should it be performed?

(04:23)
 What alternative test options are available and how do these compare to our hereditary pancreatitis test?

(08:48)
 How are results used in patient care?

Their discussion includes:

• The status of current laboratory-related legislative efforts, including the Protecting Access to Medicare Act (PAMA), the Saving Access to Laboratory Services Act (SALSA), and the Pandemic and All Hazards Preparedness Act (PAHPA).
• Current issues facing the laboratory industry, including prior authorization, coding, and potential FDA oversight of laboratory-developed tests.
• The importance of advocating on behalf of laboratories, clinicians, and patients, and engagement opportunities through professional societies like the College of American Pathologists and the American Clinical Laboratory Association.

(00:32)
 Would each of you share a little bit about yourselves and your background? Dr. Shen?

(01:25)
 Rihanna, could we have you give a little background about yourself as well?

(01:48)
 Could you provide us with an overview of Lynch syndrome?

(03:44)
 Can you expand on why genetic testing for Lynch syndrome is so important?

(06:03)
 Who would benefit from Lynch testing?

(07:51)
 Is Lynch syndrome the only type of inherited predisposition to colon cancer?

(08:48)
 Does the healthcare provider order these tests, and what kind of samples should be considered in these patients?

(10:50)
 Are there any limitations to the types of variants that can be detected by this test? And how does Mayo Clinic Laboratories ensure comprehensive results for patients?

(14:24)
 How are the results used in patient care?

(16:33)
 Could you summarize the benefits of these tests and of doing them at Mayo Clinic Laboratories?

Specific topics of discussion include:

• Background information on syphilis and the epidemic occurring in the United States.
• The report recently published by the Centers for Disease Control and Prevention (CDC) with updated laboratory recommendations for syphilis testing.
• The different testing methods used to diagnose syphilis.

(00:32)
 Can you tell us a little bit about yourself and your background?

(01:42)
 Can you please provide an overview of substance use disorders, specifically nicotine dependence, and Mayo Clinic's nicotine testing options?

(04:33)
 Which patients should have this testing and when should it be performed?

(05:54)
 What alternative test options are available and how do these compare?

(06:40)
 How are the results used in patient care?

Their discussion includes:

• How the FDA’s proposed rule on regulating LDTs has advanced to the White House Office of Management and Budget (OMB) for review, and what to expect in the coming months.
• Ongoing work around the Saving Access to Laboratory Services Act (SALSA).
• How laboratorians and pathologists can stay engaged on these important issues. 

Their discussion includes:

• A few of the major advancements in the medical field made by Black scholars, nurses, doctors, and surgeons, and important contributions to laboratory medicine by pioneering Black physicians and physician-scientists.
• Health inequities, accessibility issues, and diseases that are more prevalent in African Americans and people of lower socioeconomic status.
• How misinformation impacts preventive health measures.

Specific topics of discussion include:

• How the adrenal glands function and how tumors may affect these small, hormone-producing glands.
• Testing options for diagnosing malignant and benign tumors of the adrenal gland.
• Mayo Clinic’s use of machine learning and other innovative tools to distinguish adrenal carcinoma from common benign adrenal tumors as well as non-endocrine adrenal malignancies.

(00:32)
 Could you please tell us a little bit about your background?

(01:17)
 Could you please do a brief overview of our EOIBD test?

(03:24)
 Which patients should have this testing and when should it be performed?

(05:31)
 How are results used in patient care?

(07:02)
 What alternative test options are available and how do these compare to our test?

Their discussion includes:

• Vector-borne diseases that are causing public health concerns, and the multi-agency public health strategy recently released by the U.S. Department of Health and Human Services to address the growing problem.
• The benefits of a public-private, collaborative approach to public health, and why laboratorians need to be involved.
• Both new and reemerging diseases that are being found across the United States, and how laboratory-developed tests play a vital role in diagnosing and managing these diseases.

(00:32)
Could you please provide a little information about your background?

(02:09)
Please give a brief overview of the new test panels.

(05:35)
Which patients should have this testing and when should it be performed?

(09:49)
What alternative test options are available, and how do those compare to our testing at Mayo Clinic Laboratories?

(13:15)
How are the results used in patient care?

(00:32)
Could you provide us with a little bit about yourself and your background?

(02:56)
Would you elaborate on the role of you and the Mayo Clinic team in advancing insights with the use of mass spectrometry and its initial launch?

(05:38)
Please share about Quantitative MASS-FIX and its specificity, and which patients should have this testing and when it should be performed.

(09:42)
Is this a more simplified ordering menu?

(15:01)
Would you elaborate on how this assay supports the IMWG guidelines?

(16:01)
Are there any closing remarks you would like to add?

Their discussion includes:

• Insights from the J.P. Morgan Healthcare Conference, and where investments are happening in the diagnostics industry.
• Observations from visiting Southeast Asia around international healthcare innovation and testing accessibility. 
• The importance of private-public partnerships and investments to advance global health.

Speaker 3: (00:32)
Can you share a little about yourself and your background?

Speaker 3: (01:00)
Can you provide us with an overview of this new preeclampsia assay?

Speaker 3: (02:33)
Can you share what will be reported with this assay?

Speaker 3: (03:07)
Which patients should have this testing and at what point should it be performed?

Speaker 3: (03:35)
Can you share what alternative test options are available today for preeclampsia?

Speaker 3: (03:52)
How are the test results used in patient care?

Specific topics of discussion include:

• The history, cause, and symptoms of syphilis.
• A rare recent outbreak of ocular syphilis cases.
• The dramatic rise in syphilis and congenital syphilis cases in the United States over the last few years.
• The variety of syphilis testing options.

Their discussion includes:

• The increasing number of COVID-19 and influenza cases across the United States.
• The endemic state of COVID-19 and tools for prevention.
• The continued need to protect public health and advocate for the reauthorization of the Pandemic and All-Hazards Preparedness Act.

Show notes
(00:31)
Could you provide us a little bit about your background?

(01:20)
Could you give us a brief overview of this assay?

(02:45)
What patients should have this test and when should it be performed?

(04:25)
Could you talk a little bit about alternative test options and how they compare to our ceramides test?

(05:58)
Can you go a little bit further into how these results can impact patient care and how you may monitor patients in the future with this testing?

Show notes

Speaker 3: (00:32)
 Please give us a brief introduction of yourself and your role at Mayo Clinic.

Speaker 3: (01:44)
 Could you please expand a bit on this newly developed sequencing assay — which is a shotgun metagenomic test on CSF — and explain how it's different from other sequencing methods?

Speaker 3: (02:43)
 Could you tell us more about the specific group of patients this test would be used for and how a provider might identify those patients? When during the care process should this be ordered?

Speaker 3: (04:12)
 Could you talk about the alternative test options and how they compare?

Speaker 3: (05:42)
 How are the results used in patient care?

Show notes
(00:32)
 Would each of you share a little bit about yourselves and your backgrounds?

(01:13)
 Could you provide us with an overview of these new tests?

(02:31)
 Can you expand on why these postmortem cardiac tests are so important?

(04:09)
 Who could benefit from postmortem cardiac testing?

(05:23)
 How does a health care provider order these tests? What sample types are accepted?

(07:09)
 Is there a limit to the age of the specimen? Are there any limitations to the type of variants that can be detected by this test?

(09:07)
 What other unique features set these tests apart?

(10:17)
 How are the test results used in patient care?

(11:22)
 Could you summarize the benefits of doing these tests at Mayo?

Show notes
(00:32)
 Could you please provide us a little information about your background?

(01:46)
 Could you please give the audience a brief overview of this assay?

(03:45)
 Which patients should have this testing and when should it be performed?

(06:39)
 How are the results used in patient care?

(08:51)
 What alternative test options are available and how do they compare to our test?

Their discussion includes:

• A look back at impactful events from 2023 in laboratory medicine and diagnostics.
• What’s top of mind today heading into the holidays.
• Speculating about industry trends to expect in 2024.

Show notes
(00:32)
Could you provide a little information on your role here at Mayo Clinic?

(01:11)
 Can you give an introduction as to how GABA-A is important as the field of autoimmune neurology develops?

(02:15)
 What type of methodology are we using in this assay?

(03:17)
 Will there be a reflex to confirm positivity, or is that captured in that initial test?

(04:22)
 Is either CSF or serum specimen preferable, or do we recommend both for this biomarker?

(05:09)
 In combination with what phenotypes should this biomarker be considered?

(05:37)
 Should a physician consider adding a GABA-A receptor standalone test to our encephalopathy, epilepsy, or pediatric evaluations, to be sure they're doing a comprehensive review?

(06:25)
 Can you give us a little background on why this test is being launched by itself? Is Mayo Clinic Labs changing its stance on whether comprehensive evaluations are the most appropriate method?

(07:30)
 Why has it taken so long to bring this assay live?

(08:14)
 For exactly what type of patients should physicians consider this testing?

(10:21)
 Should physicians add our encephalopathy evaluation every time they order GABA-A? Is the presentation you just described common or a subset?

(11:24)
 Does that recommendation change in pediatric patients?

(12:20)
 What does a positive result tell physicians?

(12:57)
 Does GABA-A have a high-risk oncological association?

(13:18)
 What does GABA-A tell a pediatric neurologist if the test comes back positive?

(14:14)
 Should a positive GABA-A test lead a physician to a certain treatment option?

(15:24)
 What are you most excited about in relation to the launch of this new test?

(16:48)
 Is there anything else you'd like to add about this test?